Correlation Between Accelerate Diagnostics and Neuropace

Can any of the company-specific risk be diversified away by investing in both Accelerate Diagnostics and Neuropace at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Accelerate Diagnostics and Neuropace into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Accelerate Diagnostics and Neuropace, you can compare the effects of market volatilities on Accelerate Diagnostics and Neuropace and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Accelerate Diagnostics with a short position of Neuropace. Check out your portfolio center. Please also check ongoing floating volatility patterns of Accelerate Diagnostics and Neuropace.

Diversification Opportunities for Accelerate Diagnostics and Neuropace

-0.71

Correlation Coefficient

Accelerate Diagnostics  Neuropace

Pay attention - limited upside

The 3 months correlation between Accelerate and Neuropace is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Accelerate Diagnostics and Neuropace in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neuropace and Accelerate Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Accelerate Diagnostics are associated (or correlated) with Neuropace. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neuropace has no effect on the direction of Accelerate Diagnostics i.e., Accelerate Diagnostics and Neuropace go up and down completely randomly.

Pair Corralation between Accelerate Diagnostics and Neuropace

Given the investment horizon of 90 days Accelerate Diagnostics is expected to under-perform the Neuropace. In addition to that, Accelerate Diagnostics is 1.01 times more volatile than Neuropace. It trades about -0.03 of its total potential returns per unit of risk. Neuropace is currently generating about 0.1 per unit of volatility. If you would invest  154.00  in Neuropace on September 26, 2024 and sell it today you would earn a total of  960.00  from holding Neuropace or generate 623.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Accelerate Diagnostics  vs.  Neuropace

Accelerate Diagnostics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Accelerate Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Neuropace

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Accelerate Diagnostics and Neuropace

The main advantage of trading using opposite Accelerate Diagnostics and Neuropace positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Accelerate Diagnostics position performs unexpectedly, Neuropace can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuropace will offset losses from the drop in Neuropace's long position.

The idea behind Accelerate Diagnostics and Neuropace pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.